Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic benefits in cases of CML which were found to be resistant to treatment with imatinib (Gleevec), anoth...
For the potential treatment of various leukemias, including chronic myeloid leukemia (CML).
Massachusetts General Hospital, Boston, Massachusetts, United States
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
The Angeles Clinic and Research Institute, Santa Monica, California, United States
Novartis Investigative Site, São Paulo, SP, Brazil
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
Centro Oncologico Basilicata, Rionero in Vulture, Potenza, Italy
Unità di Oncoematologia Azienda Ospedaliera Garibaldi, Catania, Italy
Dip. di Scienze Cliniche e Biologiche - Ospedale S. Luigi Gonzaga, Orbassano, Italy
Medical faculty of the Technical University Munich, Munich, Bavaria, Germany
Novartis Investigative Site, Madrid, Spain
Novartis Investigative Site, Milano, MI, Italy
Novartis Investigative Site, Caracas, Distrito Capital, Venezuela
Chaim Sheba Medical Center, Tel-Hashomer, Israel
H Lee Moffitt Cancer Center and Research Institute Phase 2 Consortium, Tampa, Florida, United States
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States
Stanford University Hospitals and Clinics, Stanford, California, United States
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.